RadNet, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
RadNet, Inc. (RDNT) reported Revenue from Contract with Customer, Excluding Assessed Tax of $622.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-10
- RadNet, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $622.72M, a 24.99% increase year-over-year.
- RadNet, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $575.63M, a 22.11% increase year-over-year.
- RadNet, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $547.71M, a 14.80% increase year-over-year.
- RadNet, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $522.87M, a 13.39% increase year-over-year.
- RadNet, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $2.04B, a 11.51% increase from fiscal 2024.
- RadNet, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $1.83B, a 13.18% increase from fiscal 2023.
- RadNet, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.62B, a 13.05% increase from fiscal 2022.
- RadNet, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.43B, a 8.74% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $622.72M 10-Q · filed 2026-08-10 | $1.20B 10-Q · filed 2026-08-10 | $1.75B derived: sum of 3 quarters · filed 2026-08-10 | $2.27B derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $575.63M 10-Q · filed 2026-05-11 | $1.12B derived: sum of 2 quarters · filed 2026-05-11 | $1.65B derived: sum of 3 quarters · filed 2026-05-11 | $2.14B derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $547.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.07B derived: sum of 2 quarters · filed 2026-03-02 | $1.57B derived: sum of 3 quarters · filed 2026-08-10 | $2.04B 10-K · filed 2026-03-02 | |
| 2025-09-30 | $522.87M 10-Q · filed 2025-11-10 | $1.02B derived: sum of 2 quarters · filed 2026-08-10 | $1.49B 10-Q · filed 2025-11-10 | $1.97B derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $498.23M 10-Q · filed 2026-08-10 | $969.63M 10-Q · filed 2026-08-10 | $1.45B derived: sum of 3 quarters · filed 2026-08-10 | $1.91B derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $471.40M 10-Q · filed 2026-05-11 | $948.50M derived: sum of 2 quarters · filed 2026-05-11 | $1.41B derived: sum of 3 quarters · filed 2026-05-11 | $1.87B derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $477.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $938.24M derived: sum of 2 quarters · filed 2026-03-02 | $1.40B derived: sum of 3 quarters · filed 2026-03-02 | $1.83B 10-K · filed 2026-03-02 | |
| 2024-09-30 | $461.14M 10-Q · filed 2025-11-10 | $920.86M derived: sum of 2 quarters · filed 2025-11-10 | $1.35B 10-Q · filed 2025-11-10 | $1.77B derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-06-30 | $459.71M 10-Q · filed 2025-08-11 | $891.42M 10-Q · filed 2025-08-11 | $1.31B derived: sum of 3 quarters · filed 2026-03-02 | $1.71B derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-03-31 | $431.71M 10-Q · filed 2025-05-12 | $852.09M derived: sum of 2 quarters · filed 2026-03-02 | $1.25B derived: sum of 3 quarters · filed 2026-03-02 | $1.66B derived: sum of 4 quarters · filed 2026-03-02 | |
| 2023-12-31 | $420.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $822.35M derived: sum of 2 quarters · filed 2026-03-02 | $1.23B derived: sum of 3 quarters · filed 2026-03-02 | $1.62B 10-K · filed 2026-03-02 | |
| 2023-09-30 | $401.97M 10-Q · filed 2024-11-12 | $805.68M derived: sum of 2 quarters · filed 2024-11-12 | $1.20B 10-Q · filed 2024-11-12 | $1.58B derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $403.71M 10-Q · filed 2024-08-09 | $794.28M 10-Q · filed 2024-08-09 | $1.18B derived: sum of 3 quarters · filed 2025-03-03 | $1.53B derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $390.56M 10-Q · filed 2024-05-10 | $774.44M derived: sum of 2 quarters · filed 2025-03-03 | $1.12B derived: sum of 3 quarters · filed 2025-03-03 | $1.48B derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | $383.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $733.92M derived: sum of 2 quarters · filed 2025-03-03 | $1.09B derived: sum of 3 quarters · filed 2025-03-03 | $1.43B 10-K · filed 2025-03-03 | |
| 2022-09-30 | $350.04M 10-Q · filed 2023-11-09 | $704.42M derived: sum of 2 quarters · filed 2023-11-09 | $1.05B 10-Q · filed 2023-11-09 | $1.38B derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $354.38M 10-Q · filed 2023-08-09 | $696.14M 10-Q · filed 2023-08-09 | $1.03B derived: sum of 3 quarters · filed 2024-02-29 | $1.36B derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $341.77M 10-Q · filed 2023-05-10 | $674.92M derived: sum of 2 quarters · filed 2024-02-29 | $1.01B derived: sum of 3 quarters · filed 2024-02-29 | $1.34B derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $333.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $665.84M derived: sum of 2 quarters · filed 2024-02-29 | $999.76M derived: sum of 3 quarters · filed 2024-02-29 | $1.32B 10-K · filed 2024-02-29 | |
| 2021-09-30 | $332.69M 10-Q · filed 2022-11-09 | $666.61M derived: sum of 2 quarters · filed 2022-11-09 | $981.93M 10-Q · filed 2022-11-09 | $1.29B derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $333.92M 10-Q · filed 2022-08-09 | $649.24M 10-Q · filed 2022-08-09 | $957.17M derived: sum of 3 quarters · filed 2023-03-01 | $1.25B derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $315.32M 10-Q · filed 2022-05-10 | $623.25M derived: sum of 2 quarters · filed 2023-03-01 | $915.03M derived: sum of 3 quarters · filed 2023-03-01 | $1.11B derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $307.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $599.71M derived: sum of 2 quarters · filed 2023-03-01 | $790.28M derived: sum of 3 quarters · filed 2023-03-01 | $1.07B 10-K · filed 2023-03-01 | |
| 2020-09-30 | $291.78M 10-Q · filed 2021-11-09 | $482.34M derived: sum of 2 quarters · filed 2021-11-09 | $763.90M 10-Q · filed 2021-11-09 | $1.06B derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $190.57M 10-Q · filed 2021-08-09 | $472.13M 10-Q · filed 2021-08-09 | $772.97M derived: sum of 3 quarters · filed 2022-03-01 | $1.07B derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $281.56M 10-Q · filed 2021-05-10 | $582.40M derived: sum of 2 quarters · filed 2022-03-01 | $875.10M derived: sum of 3 quarters · filed 2022-03-01 | $1.16B derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | $300.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $593.53M derived: sum of 2 quarters · filed 2022-03-01 | $882.63M derived: sum of 3 quarters · filed 2022-03-01 | $1.15B 10-K · filed 2022-03-01 | $1.03B 10-K · filed 2020-03-16 |
| 2019-09-30 | $292.69M 10-Q · filed 2020-11-09 | $581.79M derived: sum of 2 quarters · filed 2020-11-09 | $853.34M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $289.10M 10-Q · filed 2020-08-10 | $560.65M 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $975.15M 10-K · filed 2021-03-16 | $868.74M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |